SLCO1B3 and metabolic dysfunction-associated steatotic liver disease: Through network pharmacology screening and in vitro and in vivo experimental validation, it was discovered that isorhamnetin can regulate bile acid metabolism by upregulating FXR and BSEP and downregulating SLCO1B3, thereby alleviating bile acid accumulation in the liver of NAFLD, thus playing a role in mitigating NAFLD.